由G蛋白结合受体驱动的肠道葡萄糖类-1重编程用于肥胖:希望还是作?
Mohan Patil1, Ilaria Casari1, Leon N Warne2
1Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia 6102, Australia.
口服的多-GPCR激活剂疗法通过增强葡萄糖类-1 (GLP-1) 分泌来治疗肥胖症具有前景. 这种方法为当前的注射疗法和减肥手术提供了潜在的替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
背景情况:
- 肥胖,被称为"全球性",是全球性重大健康挑战.
- 目前的口服肥胖药物疗法具有有限的疗效和副作用.
- 葡萄糖类-1 (GLP-1) 生物学对代谢调节至关重要,并刺激了对治疗类型的兴趣.
研究的目的:
- 审查潜在的基于G蛋白结合受体 (GPCR) 的策略,用于口服的多GPCR激动剂治疗.
- 讨论补充GPCR途径用于增强内源GLP-1分泌的药理学.
- 批判性地评估口服聚-GPCR激素对减肥的治疗潜力和局限性.
主要方法:
- 对GPCRs和GLP-1分泌物的现有文献的审查.
- 分析双/多GPCR的激进作用,作为传统单GPCR方法的替代方案.
- 讨论口服多GPCR药物发现的最新进展.
主要成果:
- 几十年的GPCR研究没有产生经批准的口服GLP-1分泌物.
- 双/多GPCR激应正在成为一个有前途的战略.
- 口服的多GPCR激动剂旨在增强肠道GLP-1的体重控制作用.
结论:
- 口服聚-GPCR激进症为肥胖提供了一种新的治疗途径.
- 这种方法可以克服目前注射GLP-1疗法和手术的局限性.
- 需要进一步的研究和开发,才能充分发挥口服多GPCR激动剂的潜力.
更多相关视频
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GPCRs Regulate Adenylyl Cylase Activity
Regulation of Food Intake
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Insulin: The Receptor and Signaling Pathways
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
